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In the methods, can you provide some more reasoning behind the choices for of the inclusion criteria 2 and 3. * This has been done later on in the manuscript. It might be useful to indicate that these reasons will be explained.
Who decided on what were 'common' materials and implant types. Please provide more details on how these were decided upon.
'To prevent the review from becoming unwieldy' (used twice).....please find a different way to describe this and make sure all decisions on what is and what isn't included as objective as possible. Give reasoning why older guidelines are being excluded
REVIEWER
Harman Chaudhry McMaster University, Canada REVIEW RETURNED 12-Feb-2018 GENERAL COMMENTS I would commend the authors for a very timely protocol. The issue of implants/devices, especially in orthopaedic surgery and other procedural disciplines, is coming under increasing public scrutiny. The approval of implants and devices is not nearly as rigorous as that of pharmaceuticals. Moreover, post-market surveillance is often less rigorous as well. However, the impact of defective or poorly engineered implants is devastating. Exploring how different global jurisdictions deal with device approval (i.e. engineering standards) is an important public health question. This protocol has the potential to push forward the conversation on an important subject that all governments must address. We would like to thank the reviewer for their comments and the time and effort they have put into reviewing our paper so that it may be improved.
Introduction -'riskiest' in what sense? It would be helpful for non-specialist readers to have more explicit reasons why revision surgery is detrimental.
Orthopaedic implants mostly have class 3 status in FDA regulations marking them out as being of the highest risk. In our revision we have clarified this point as well as adding additional information around the risks of revision surgery more generally.
We have provided further explanation for our choices of inclusion criteria within the inclusion criteria section.
The materials we have chosen to study in our review were decided on after consultation with subject experts in orthopaedic implants on our review team. Literature searches were then performed to identify any additional materials that should be included. We have added two new references to further justify our materials choice.
Our implant choice was informed by the most recent National Joint Registry report. It shows the vast majority of implants used in the UK are hip and knee prostheses. Whilst we agree it is a potential limitation not to include all implants, we believe engineering standards for hip and knee prostheses are the most relevant to our intended audience.
'To prevent the review from becoming unwieldy' (used twice).....please find a different way to describe this and make sure all decisions on what is and what isn't included as objective as possible.
We have replaced these terms and expanded the reasoning for our studies choice of countries.
Give reasoning why older guidelines are being excluded
We have removed this requirement as our early scoping searches have shown that standards are usually reviewed and renewed at least every ten years and often more frequently. Therefore this limitation was unnecessary.
Reviewer: 2 Reviewer Name: Harman Chaudhry Institution and Country: McMaster University, Canada Please state any competing interests: None Please leave your comments for the authors below
We would like to thank the reviewer for their comments and agree with their sentiments about implant regulation and its potential impact.
I would commend the authors for a very timely protocol.
The issue of implants/devices, especially in orthopaedic surgery and other procedural disciplines, is coming under increasing public scrutiny. The approval of implants and devices is not nearly as rigorous as that of pharmaceuticals. Moreover, post-market surveillance is often less rigorous as well. However, the impact of defective or poorly engineered implants is devastating. Exploring how different global jurisdictions deal with device approval (i.e. engineering standards) is an important public health question. This protocol has the potential to push forward the conversation on an important subject that all governments must address.
Strengths: 1. Excellent rationale and background information, from well-cited and current references. 2. Use of standardized systematic review framework (PRISMA) 3. Use of a librarian and scoping reviews to identify appropriate databases where the information may be found.
Comprehensive and broad search terminology
Weaknesses/Issues for further consideration: 1. By design, this review will not necessarily capture all existing engineering standards. As the authors acknowledge, not all engineering standards will be published online. Is there any role for involvement in subject experts, who can direct the study team towards engineering standards not available online. In other words, not all publicly available engineering standards will be online. There may be publicly available engineering standards that exist only in material form (e.g. a booklet).
We have looked closely at how we can improve our data collection to provide a comprehensive review of engineering standards. We feel that as a study we have established groups of experts in systematic review methodology (AM, MU,EK), orthopaedic surgery and medicine across multiple countries (AM, RK, JA,MU), implant testing and mechanical engineering (DL, MW and JM) and product evaluation and standards (MW). That said we would like to add three new co-authors (FO, VM and JM) who have assisted greatly in refining the work and the studies search strategy, and add to the appropriate expertise. Scoping searches have shown our previous strategy has worked well in the G20 group of nation but is less effective in the G23 who are less likely to publish standards online.
Our three new co-authors expand our expertise in this area and we have been greatly assisted by Dr Otsyeno and Dr Mutiso in developing a plan appropriate to the developing nations and also in engaging the Kenyan Bureau of Standards, which has informed our scoping searches and protocol. Dr Madete has expertise and establishing standards for medical devices in Keyna and is an expert in orthopaedic engineering in Africa and she has also contributed to the development of the plan and specifically the method for engaging partners in other developing countries, which she has experience in.
2. The analysis is largely qualitative. However, there may be a role for quantitative analysis as well. In general, the analysis appears to be the least well developed aspect of the protocol. Is there a role for piloting a few engineering standard documents/studies to determine the type of information that will be gathered, and what type of statistical analysis can be performed? Indeed, if in the end not all standards are reported equally, certain proposed analyses may need to be abandoned; however, I would suggest proposing specific analyses a priori is a more robust study design.
Thank you for your comments around our analysis section, it is true it was the least developed area of our protocol and we have taken steps to address this. Our scoping searches have found most nations adhere to either ISO or ASTM standards, sometimes both. Few if any develop their own standards, this makes in depth quantitative analysis difficult, although we have not performed the full review and remain unaware of the use of standards in many countries. That said we have provided details of the quantitative analysis we will perform if the opportunity arises in our statistical analysis section, we hope the reviewer agrees the protocol has been clarified and improved in this regard.
